Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VABu Conditioning Regimen in AML Patients Undergoing Stem Cell Transplantation
NCT07762508Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Aug 2026
- Primary completion
- Jul 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax, azacitidine and busulfan in acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall Survival at 2 years. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
venetoclaxazacitidinebusulfan
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07762508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07762508.